Celcuity Inc. (CELC) Investor Relations Documents

Celcuity Inc. (CELC) investor relations documents from the company's IR site: 3 presentations, 22 press releases; latest deck 2026-07-14. Read in-app with summaries. First-party data.

Corporate Presentation - July 2026: REVTORPYK is FDA-approved for HR+/HER2- metastatic breast cancer, offering a new pan-PI3K, mTORC1/2 inhibitor treatment.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13Press releaseCelcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-06Press releaseCelcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
2026-07-30Press releaseNewly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Prac
2026-07-14PresentationCorporate Presentation - July 2026
2026-07-14Press releaseCelcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Adv
2026-06-03Press releaseCelcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
2026-06-03Press releaseCelcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
2026-06-02PresentationCelcuity Investor Conference Call Presentation
2026-06-02Press releaseCelcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Comp
2026-06-01Press releaseCelcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Tria
2026-05-28Press releaseCelcuity To Participate in Upcoming Investor Conferences
2026-05-14Press releaseCelcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expand
2026-05-14Press releaseCelcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07Press releaseRead More
2026-05-01Press releaseCelcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free
2026-03-25Press releaseRead More
2026-03-18Press releaseRead More
2026-03-09Press releaseRead More
2026-02-25Press releaseRead More
2026-02-12Press releaseRead More
2026-02-04Press releaseRead More
2026-01-20Press releaseRead More
2025-10-20PresentationPhase 3 VIKTORIA-1 HR+/HER2-/PIK3CA WT Trial Results – Oct 20, 2025
Press releaseRead More
Press releaseRead More

CELC overview · CELC earnings · CELC financials · CELC KPIs · CELC documents · CELC ownership · CELC peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.